Holen Sie sich die Stockscreener-App
369.06
1.34%
-5.02
Schlusskurs vom Vortag:
$374.08
Offen:
$372.57
24-Stunden-Volumen:
422.24K
Relative Volume:
1.15
Marktkapitalisierung:
$41.75B
Einnahmen:
$5.76B
Nettoeinkommen (Verlust:
$514.49M
KGV:
82.36
EPS:
4.4813
Netto-Cashflow:
$1.10B
1W Leistung:
+4.12%
1M Leistung:
+6.03%
6M Leistung:
+15.08%
1J Leistung:
+16.05%
1-Tages-Spanne:
$367.30
$375.90
1-Wochen-Bereich:
$344.94
$375.90
52-Wochen-Spanne:
$253.95
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, MRNA, REGN, ARGX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-13 | Hochstufung | Jefferies | Hold → Buy |
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Barclays | Overweight |
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
All You Need to Know About BeOne Medicines Ltd.Sponsored ADR (ONC) Rating Upgrade to Strong Buy - Zacks Investment Research
ONC Q2 2026 Earnings: Reported EPS of 13.8375 as Shares Slip 0.2%Revenue Growth Report - dars.gov.et
ONC Q2 2026 Earnings: Reported EPS of 13.8375 as Shares Slip 0.2%Basic EPS Analysis - https://www.dars.gov.et/
Under a trading plan, BeOne Medicines (ONC) counsel sells 1,115 depositary shares at $375. - Stock Titan
Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com - Investing.com Canada
Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 4 BeOne Medicines Ltd. For: 1 October - Investing.com India
After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares. - Stock Titan
ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge LowerEarnings Volatility Report - dars.gov.et
ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge LowerEPS Estimate Trend - dars.gov.et
ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge LowerConsensus Beat Rate - www.dars.gov.et
BeOne Medicines (ONC) insiders exercise options for 30,768 ADS - Stock Titan
BeOne Medicines (ONC) backer Baker Bros. funds $1.1M employee ADS option exercise - Stock Titan
Engineers Gate Manager LP Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Xiaodong Wang Sells 38,287 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (ONC) director trades ADS under preset plan - Stock Titan
Squarepoint Ops LLC Boosts Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Baird Financial Group Inc. Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Public Employees Retirement System of Ohio Invests $2.14 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $1.91 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Insider Sells $46,973.52 in Stock - MarketBeat
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeSmart Money Flow Stocks - careplusvn.com
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeBPI Bear Correction - siam.in
BeOne (ONC) accounting chief sells ADS to cover RSU taxes - Stock Titan
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeHigh Volume Node - dars.gov.et
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeInside Day Breakout - dars.gov.et
BeOne Medicines (NASDAQ: ONC) insider to sell 132 ADS after vesting - Stock Titan
BeOne Medicines Ltd.Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
BeOne Medicines COO Wu Xiaobin Executes ADS Sale Under Rule 10b5-1 Trading Plan - Kalkine Media
BeOne Medicines Ltd.Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
BeOne Medicines (NASDAQ: ONC) ex-director lines up $788K ADS sale - Stock Titan
BeOne (ONC) Earnings Snapshot: Available Data Shows the Latest Reported Performance for This Review; Trading Response: The Share Price Adds 1.44% in Latest TradingEPS Surprise History - dars.gov.et
BeOne Medicines stock rises nearly 4% as buyers control session amid bullish technicals - Traders Union
BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia - Sahm
BeOne Medicines (NASDAQ:ONC) SVP Sells 2,666 Shares of Stock - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $25,661,243.30 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells $19,659,569.80 in Stock - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Generali Investments Management Co LLC Buys Shares of 8,000 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
The Manufacturers Life Insurance Company Trims Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Charles Schwab Trust Co Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
ONC Q2 2026 Earnings: EPS of $13.84 Signals Strong Quarter as Shares Rise 3.08%Earnings Cycle Report - dars.gov.et
Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines shares gain about 5.5% after robust Q2 results and new Phase 3 trials announcement - Traders Union
BeOne Medicines Ltd.Sponsored ADR $ONC Shares Bought by Bank of America Corp DE - MarketBeat
BeOne Medicines Q2 Earnings Call Highlights - sharewise.com
BeOne Medicines (NASDAQ:ONC) CFO Sells $361,805.47 in Stock - MarketBeat
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beone Medicines Ltd Adr-Aktie (ONC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Oct 13 '26 |
Sale |
350.99 |
31,027 |
10,890,074 |
0 |
| Lee Chan Henry | SVP, General Counsel |
Sep 30 '26 |
Sale |
375.00 |
1,115 |
418,125 |
0 |
| CHAN LEE | Officer |
Sep 30 '26 |
Proposed Sale |
365.27 |
1,115 |
407,276 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 28 '26 |
Sale |
364.79 |
31,028 |
11,318,558 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 28 '26 |
Option Exercise |
36.90 |
31,028 |
1,144,933 |
31,028 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 08 '26 |
Sale |
349.10 |
38,287 |
13,366,092 |
0 |
| XIAODONG WANG | Director |
Sep 08 '26 |
Proposed Sale |
358.26 |
131,370 |
47,064,616 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 08 '26 |
Option Exercise |
36.90 |
31,027 |
1,144,896 |
31,027 |
| TITUS BENJAMIN BALL | Officer |
Sep 01 '26 |
Proposed Sale |
355.86 |
132 |
46,974 |
0 |
| Ball Titus B. | Principal Accounting Officer |
Sep 01 '26 |
Sale |
355.86 |
132 |
46,974 |
0 |
5.97%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):